67 results
ARS
2024 FY
CCCC
C4 Therapeutics Inc
30 Apr 24
Annual report to shareholders
8:52am
to terminate the Roche Agreement on a target-by-target basis by the entry into a mutual target termination agreement. Upon a termination of this nature … , including the FDA in the United States, will agree with our assessment of whether extensions of this nature should be granted and, even if granted
8-K
CCCC
C4 Therapeutics Inc
4 Mar 24
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins
7:05am
and warranties, covenants and indemnification obligations for a transaction of this nature. The License Agreement became effective upon signing and will continue
8-K
xry5t4 uj
12 Dec 23
Entry into a Material Definitive Agreement
7:15am
8-K
bgeogrpe
30 May 23
Entry into a Material Definitive Agreement
7:30am
8-K
EX-10.2
efib60kc y9wy3kly
30 May 23
Entry into a Material Definitive Agreement
7:30am
8-K
EX-10.1
jz42 qp6cftwem
30 May 23
Entry into a Material Definitive Agreement
7:30am
ARS
94cr3uavmfz0615
28 Apr 23
Annual report to shareholders
7:03am
PRE 14A
40yif1gg666
18 Apr 23
Preliminary proxy
7:59am